Evidence map›Paper›PMID 33615660›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Enhanced Live-Cell Delivery of Synthetic Proteins Assisted by Cell-Penetrating Peptides Fused to DABCYL.

Shaswati Mandal, Guy Mann, Gandhesiri Satish, Ashraf Brik

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shaswati MandalSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, 3200008, Haifa, Israel.
Guy MannSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, 3200008, Haifa, Israel.
Gandhesiri SatishSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, 3200008, Haifa, Israel.
Ashraf BrikSchulich Faculty of Chemistry, Technion-Israel Institute of Technology, 3200008, Haifa, Israel.ORCID 0000-0001-8745-2250
Technion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Live-cell delivery of a fully synthetic protein having selectivity towards a particular target is a promising approach with potential applications for basic research and therapeutics. Cell-penetrating peptides (CPPs) allow the cellular delivery of proteins but mostly result in endosomal entrapment, leading to lack of bioavailability. Herein, we report the design and synthesis of a CPP fused to 4-((4-(dimethylamino)phenyl)azo)benzoic acid (DABCYL) to enhance cellular uptake of fluorescently labelled synthetic protein analogues in low micromolar concentration. The attachment of cyclic deca-arginine (cR10) modified with a single lysine linked to DABCYL to synthetic ubiquitin (Ub) and small ubiquitin-like modifier-2 (SUMO-2) scaffolds resulted in a threefold higher uptake efficacy in live cells compared to the unmodified cR10. We could also achieve cR10DABCYL-assisted delivery of Ub and a Ub variant (Ubv) based activity-based probes for functional studies of deubiquitinases in live cells.

Indexed as

Cell Line, TumorCell-Penetrating PeptidesFluorescenceHumansMolecular Structurep-DimethylaminoazobenzeneSmall Ubiquitin-Related Modifier ProteinsUbiquitin4-(4-dimethylaminophenylazo)benzoic acidCell-Penetrating Peptidesp-DimethylaminoazobenzeneSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanUbiquitinactivity-based probescell-penetrating peptidesfluorescencesmall ubiquitin like modifier (SUMO)ubiquitin

Identifiers

PMID33615660
PMCPMC8048964
OpenAlexW3131507366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.